Sam Deprimo

Sam DePrimo has built a strong foundation in the field of translational medicine and biomarkers throughout their work experience. Starting as a Post Doctoral Fellow at the Cleveland Clinic Foundation in 1996, they later held roles at Stanford University School of Medicine, Sugen, Pfizer, Exelixis, and Johnson & Johnson. Most recently, they served as the Associate Director of Translational Biology at Zentalis Pharmaceuticals before taking on the role of Director of Clinical Biomarkers at Poseida Therapeutics, Inc.

Sam DePrimo earned a PhD in Molecular Genetics from the University of Cincinnati College of Medicine.